These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 9764962)
1. Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer's disease. Fontana RJ; deVries TM; Woolf TF; Knapp MJ; Brown AS; Kaminsky LS; Tang BK; Foster NL; Brown RR; Watkins PB Br J Clin Pharmacol; 1998 Sep; 46(3):221-8. PubMed ID: 9764962 [TBL] [Abstract][Full Text] [Related]
2. The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity. Fontana RJ; Turgeon DK; Woolf TF; Knapp MJ; Foster NL; Watkins PB Hepatology; 1996 Jun; 23(6):1429-35. PubMed ID: 8675160 [TBL] [Abstract][Full Text] [Related]
3. Tacrine is not an ideal probe drug for measuring CYP1A2 activity in vivo. Larsen JT; Hansen LL; Brosen K Br J Clin Pharmacol; 1999 Nov; 48(5):663-8. PubMed ID: 10594467 [TBL] [Abstract][Full Text] [Related]
4. Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans. Rasmussen BB; Brøsen K Br J Clin Pharmacol; 1997 Mar; 43(3):253-8. PubMed ID: 9088579 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. Carrillo JA; Christensen M; Ramos SI; Alm C; Dahl ML; Benitez J; Bertilsson L Ther Drug Monit; 2000 Aug; 22(4):409-17. PubMed ID: 10942180 [TBL] [Abstract][Full Text] [Related]
6. Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements. Tang BK; Zhou Y; Kadar D; Kalow W Pharmacogenetics; 1994 Jun; 4(3):117-24. PubMed ID: 7920691 [TBL] [Abstract][Full Text] [Related]
7. Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy. Laine K; Palovaara S; Tapanainen P; Manninen P Clin Pharmacol Ther; 1999 Dec; 66(6):602-8. PubMed ID: 10613616 [TBL] [Abstract][Full Text] [Related]
8. Influence of the urine flow rate on some caffeine metabolite ratios used to assess CYP1A2 activity. Sinués B; Fanlo A; Bernal ML; Mayayo E; Soriano MA; Martínez-Ballarin E Ther Drug Monit; 2002 Dec; 24(6):715-21. PubMed ID: 12451287 [TBL] [Abstract][Full Text] [Related]
9. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios. Begas E; Kouvaras E; Tsakalof A; Papakosta S; Asprodini EK Biomed Chromatogr; 2007 Feb; 21(2):190-200. PubMed ID: 17221922 [TBL] [Abstract][Full Text] [Related]
10. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Fuhr U; Rost KL Pharmacogenetics; 1994 Jun; 4(3):109-16. PubMed ID: 7920690 [TBL] [Abstract][Full Text] [Related]
11. [Determination of caffeine metabolite for the evaluation of N-acetyltransferase, CYP1A2 and xanthine oxidase activities]. Lu JF; Yi T; Cao XM; Zhuo HT; Ling SS Yao Xue Xue Bao; 1997 Nov; 32(11):813-8. PubMed ID: 11596199 [TBL] [Abstract][Full Text] [Related]
12. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Relling MV; Lin JS; Ayers GD; Evans WE Clin Pharmacol Ther; 1992 Dec; 52(6):643-58. PubMed ID: 1458773 [TBL] [Abstract][Full Text] [Related]
13. Consumption of charcoal-broiled meat as an experimental tool for discerning CYP1A2-mediated drug metabolism in vivo. Larsen JT; Brøsen K Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):141-8. PubMed ID: 16128907 [TBL] [Abstract][Full Text] [Related]
14. Caffeine metabolism before and after liver transplantation. Bechtel YC; Lelouët H; Hrusovsky S; Brientini MP; Mantion G; Paintaud G; Miguet JP; Bechtel PR Int J Clin Pharmacol Ther; 2001 Feb; 39(2):53-60. PubMed ID: 11270802 [TBL] [Abstract][Full Text] [Related]
15. Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow. Sinués B; Sáenz MA; Lanuza J; Bernal ML; Fanlo A; Juste JL; Mayayo E Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):159-66. PubMed ID: 10067814 [TBL] [Abstract][Full Text] [Related]
16. Validation of urine caffeine metabolite ratios with use of stable isotope-labeled caffeine clearance. Denaro CP; Wilson M; Jacob P; Benowitz NL Clin Pharmacol Ther; 1996 Mar; 59(3):284-96. PubMed ID: 8653991 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics. Perera V; Gross AS; Xu H; McLachlan AJ J Pharm Pharmacol; 2011 Sep; 63(9):1161-8. PubMed ID: 21827488 [TBL] [Abstract][Full Text] [Related]
18. The effect of liver disease on urine caffeine metabolite ratios. Denaro CP; Wilson M; Jacob P; Benowitz NL Clin Pharmacol Ther; 1996 Jun; 59(6):624-35. PubMed ID: 8681487 [TBL] [Abstract][Full Text] [Related]
19. [Effect of Tibetan medicine zuotai on the activity, protein and mRNA expression of CYP1A2 and NAT2]. Li XY; Liu YN; Li YP; Zhu JB; Yao XC; Li YF; Yang M; Yuan M; Fan XR; Yin YM Yao Xue Xue Bao; 2014 Feb; 49(2):267-72. PubMed ID: 24761621 [TBL] [Abstract][Full Text] [Related]
20. Severe 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) intoxication: insights into the measurement of hepatic cytochrome P450 1A2 induction. Abraham K; Geusau A; Tosun Y; Helge H; Bauer S; Brockmöller J Clin Pharmacol Ther; 2002 Aug; 72(2):163-74. PubMed ID: 12189363 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]